作者
Sachin K Aggarwal, Lan Jiang, Ge Liu, Monika E Grabowska, Henry H Ong, Russell A Wilke, QiPing Feng, Wei-Qi Wei
发表日期
2024/4/1
期刊
JACC: Advances
卷号
3
期号
4
页码范围
100894
出版商
American College of Cardiology Foundation
简介
Background
Statins reduce low-density lipoprotein cholesterol (LDL-C) and are efficacious in the prevention of atherosclerotic cardiovascular disease (ASCVD). Dose-response to statins varies among patients and can be modeled using 3 distinct pharmacological properties: 1) E0 (baseline LDL-C), 2) ED50 (potency: median dose achieving 50% reduction in LDL-C); and 3) Emax (efficacy: maximum LDL-C reduction). However, individualized dose-response and its association with ASCVD events remains unknown.
Objectives
The authors analyzed the relationship between ED50 and Emax with real-world cardiovascular disease outcomes.
Methods
We leveraged deidentified electronic health record data to identify individuals exposed to multiple doses of the 3 most commonly prescribed statins (atorvastatin, simvastatin, or rosuvastatin) within the context of their longitudinal health care. We derived ED50 and E …
学术搜索中的文章
SK Aggarwal, L Jiang, G Liu, ME Grabowska, HH Ong… - JACC: Advances, 2024